Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of parkinson's disease

Folia Histochemica et Cytobiologica

Volumn 50, Issue 2, 2012, Pages 228-238

  Hacioglu, Gulay ^a   Seval Celik, Yasemin ^a   Tanriover, Gamze ^a   Ozsoy, Ozlem ^a   Saka Topcuoglu, Esen ^b   Balkan, Sevin ^a   Agar, Aysel ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Akt p akt; Bcl 2; Docosahexaenoic acid; Dopaminergic neuron survival; MPTP; Parkinson's disease; Rat

Indexed keywords

DOCOSAHEXAENOIC ACID; PROTEIN BCL 2; PROTEIN KINASE B; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOTOR ACTIVITY; MOTOR COORDINATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; WISTAR RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84863868047     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0032     Document Type: Article

References (120)

1. Lopez GH, Ilincheta de Boschero MG, Castagnet PI, Giusto NM. Age-associated changes in the content and fatty acid composition of brain glycerophospholipids. Comp Biochem Physiol B Biochem Mol Biol. 1995;112:331-343.
2. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci. 2000;18:383-399.
3. Okuyama H. Minimum requirements of n-3 and n-6 essential fatty acids for the function of the central nervous system and for the prevention of chronic disease. Proc Soc Exp Biol Med. 1992;200:174-176.
4. Chalon S, Delion-Vancassel S, Belzung C et al. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr. 1998;128:2512-2519.
5. Kidd PM. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev. 2000;5:502-529.
6. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415-55.
7. Marchetti B, Serra PA, Tirolo C et al. Glucocorticoid receptor- nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions. Brain Res Brain Res Rev. 2005;48:302-321.
8. Yuan H, Zhang ZW, Liang LW et al. Treatment strategies for Parkinson's disease. Neurosci Bull. 2010;26:66-76.
9. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, ed. Movement Disorders 2. London: Butterworth; 1987:166-230.
10. Hartmann A, Hunot S, Michel PP et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA. 2000;97:2875-2880.
11. Da Cunha C, Angelucci ME, Canteras NS, Wonnacott S, Takahashi RN. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell Mol Neurobiol. 2002;22:227-237.
12. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 1983;80:4546-4550.
13. Langston JW, Irwin I. MPTP: current concepts and controversies. Clin Neuropharmacol. 1986;9:485-507.
14. Selvaraj S, Watt JA, Singh BB. TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/ /MPP(+). Cell Calcium. 2009;46:209-218.
15. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM, Kopin IJ. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull. 1984;20:548-553.
16. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism- inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6- -tetrahydropyridine: uptake of the metabolite N-methyl-4- -phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA. 1985;82:2173-2177.
17. Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE. MPTP, MPP+ and mitochondrial function. Life Sci. 1987;40:721-729.
18. Lotharius J, Dugan LL, O'Malley KL. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci. 1999;19:1284-1293.
19. Vila M, Jackson-Lewis V, Vukosavic S et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4- -phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA. 2001;98:2837-2842.
20. Akbar M, Calderon F, Wen Z, Kim HY. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci USA. 2005;102:10858-10863.
21. Seo JH, Rah JC, Choi SH et al. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 2002;16:1826-1828.
22. Matsuzaki H, Tamatani M, Mitsuda N et al. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem. 1999;73:2037-2046.
23. Pugazhenthi S, Nesterova A, Sable C et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2000;275:10761-10766.
24. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl- -1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500-506.
25. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
26. Parkinson Study Group. A controlled, randomized, delayedstart study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
27. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241-248.
28. Hacioglu G, Agar A, Yargicoglu P. The role of docosahexaenoic acid on visual evoked potentials in one kidney-one clip hypertension. Acta Ophthalmol Scand. 2006;84:488-494.
29. Hacioglu G, Kose O, Aslan M, Agar A. Beneficial effects of docosahexaenoic acid on active avoidance performance in 1K-1C hypertensive rats. Neurobiol Learn Mem. 2007;87: 159-165.
30. Kremer JM, Lawrence DA, Jubiz W et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum. 1990;33:810-820.
31. Ozsoy O, Tanriover G, Derin N et al. The effect of docosahexaenoic acid on visual evoked potentials in a mouse model of Parkinson's Disease: the role of cyclooxygenase-2 and Nuclear Factor Kappa-B. Neurotox Res. 2011; Jan 14 [Epub ahead of print].
32. Simopoulos AP. Summary of the NATO advanced research workshop on dietary omega 3 and omega 6 fatty acids: biological effects and nutritional essentiality. J Nutr. 1989;119: 521-528.
33. Tanriover G, Seval-Celik Y, Ozsoy O et al. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease. Folia Histochem Cytobiol. 2010;48:434-441.
34. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods. 2005;148:78-87.
35. Pellegrino LJ, Pellegrino AS, Cushman AJ. Stereotaxic Atlas of the Rat Brain. New York: Plenum Press; 1979.
36. Crawley J. What's wrong with my mouse? Behavioral phenotyping of transgenic and knockout mice. New York: Wiley- -Liss; 2000.
37. Papeschi R, Theiss P, Ayhan H. AMT catalepsy and hypokinesia: interaction with morphine and cocaine. Psychopharmacologia. 1976;46(2):149-57.
38. Quesada A, Lee BY, Micevych PE. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev Neurobiol. 2008;68:632-644.
39. Stromberg I, Bjorklund H, Dahl D, Jonsson G, Sundstrom E, Olson L. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- -tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res Bull. 1986;17:225-236.
40. Heikkila RE, Nicklas WJ, Duvoisin RC. Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4- -phenylpyridinium ion (MPP+) to rats. Neurosci Lett. 1985;59:135-140.
41. Sirinathsinghji DJ, Heavens RP, Richards SJ, Beresford IJ, Hall MD. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway-I. Behavioural, neurochemical and histological characterization of the lesion. Neuroscience. 1988;27:117-128.
42. Takada M, Li ZK, Hattori T. Intracerebral MPTP injections in the rat cause cell loss in the substantia nigra, ventral tegmental area and dorsal raphe. Neurosci Lett. 1987;78:145-150.
43. Takada M, Li ZK, Hattori T. Dopaminergic nigrotectal projection in the rat. Brain Res. 1988;457:165-168.
44. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318:215-224.
45. Viswanath V, Wu Y, Boonplueang R, et al. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci. 2001;21:9519-9528.
46. Bousquet M, Saint-Pierre M, Julien C, Salem N, Jr., Cicchetti F, Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J. 2008;22:1213-1225.
47. Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ. Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci Res. 2008;62:206-209.
48. Toit-Kohn JL, Louw L, Engelbrecht AM. Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways. J Nutr Biochem. 2009;20:106-114.
49. Haobam R, Sindhu KM, Chandra G, Mohanakumar KP. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav Brain Res. 2005;163:159-167.
50. Capitelli C, Sereniki A, Lima MM, Reksidler AB, Tufik S, Vital MA. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol. 2008;594:101-108.
51. Kato H, Kurosaki R, Oki C, Araki T. Arundic acid, an astrocyte- modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res. 2004;1030:66-73.
52. Leret ML, San Millan JA, Fabre E, Gredilla R, Barja G. Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. Toxicology. 2002;170:165-171.
53. Mitra N, Mohanakumar KP, Ganguly DK. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res Bull. 1992;28:355-364.
54. Sedelis M, Schwarting RK, Huston JP. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res. 2001;125:109-125.
55. Samadi P, Gregoire L, Rouillard C, Bedard PJ, Di Paolo T, Levesque D. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol. 2006;59:282-288.
56. Abdulwahid Arif I, Ahmad Khan H. Environmental toxins and Parkinson's disease: putative roles of impaired electron transport chain and oxidative stress. Toxicol Ind Health. 2010;26:121-128.
57. Mizuno Y, Suzuki K, Sone N, Saitoh T. Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brains. Neurosci Lett. 1987;81:204-208.
58. Mills RD, Sim CH, Mok SS, Mulhern TD, Culvenor JG, Cheng HC. Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1). J Neurochem. 2008;105:18-33.
59. Crompton M. Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr Opin Cell Biol. 2000;12:414-419.
60. Lee DH, Szczepanski M, Lee YJ. Role of Bax in quercetininduced apoptosis in human prostate cancer cells. Biochem Pharmacol. 2008;75:2345-2355.
61. Reed JC. Double identity for proteins of the Bcl-2 family. Nature. 1997;387:773-776.
62. Biswas SC, Shi Y, Sproul A, Greene LA. Pro-apoptotic Bim induction in response to nerve growth factor deprivation requires simultaneous activation of three different death signaling pathways. J Biol Chem. 2007;282:29368-29374.
63. Liu XM, Pei DS, Guan QH et al. Neuroprotection of Tat- GluR6-9c against neuronal death induced by kainate in rat hippocampus via nuclear and non-nuclear pathways. J Biol Chem. 2006;281:17432-17445.
64. Pei DS, Wang XT, Liu Y et al. Neuroprotection against ischaemic brain injury by a GluR6-9c peptide containing the TAT protein transduction sequence. Brain. 2006;129:465-479.
65. Rezende AC, Vieira AS, Rogerio F et al. Effects of systemic administration of ciliary neurotrophic factor on Bax and Bcl-2 proteins in the lumbar spinal cord of neonatal rats after sciatic nerve transection. Braz J Med Biol Res. 2008;41:1024-1028.
66. Zhang Z, Lapolla SM, Annis MG et al. Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to capture activated Bax. J Biol Chem. 2004;279:43920-43928.
67. Patel JR, Brewer GJ. Age-related differences in NFkappaB translocation and Bcl-2/Bax ratio caused by TNFalpha and Abeta42 promote survival in middle-age neurons and death in old neurons. Exp Neurol. 2008;213:93-100.
68. Mohan J, Gandhi AA, Bhavya BC et al. Caspase-2 triggers Bax-Bak-dependent and -independent cell death in colon cancer cells treated with resveratrol. J Biol Chem. 2006;281:17599-17611.
69. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312-1316.
70. Fennell DA, Corbo M, Pallaska A, Cotter FE. Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK11195 involves de novo generation of reactive oxygen species. Br J Cancer. 2001;84:1397-1404.
71. Kowaltowski AJ, Fenton RG, Fiskum G. Bcl-2 family proteins regulate mitochondrial reactive oxygen production and protect against oxidative stress. Free Radic Biol Med. 2004;37:1845-1853.
72. Blum D, Torch S, Lambeng N et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol. 2001;65:135-172.
73. Cassarino DS, Parks JK, Parker WD, Jr., Bennett JP, Jr. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta. 1999;1453:49-62.
74. Chinnaiyan AM, Orth K, O'Rourke K, Duan H, Poirier GG, Dixit VM. Molecular ordering of the cell death pathway. Bcl- 2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem. 1996;271:4573-4576.
75. Offen D, Beart PM, Cheung NS et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA. 1998;95:5789-5794.
76. Yang L, Matthews RT, Schulz JB et al. 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci. 1998;18:8145-8152.
77. O'Malley KL, Liu J, Lotharius J, Holtz W. Targeted expression of BCL-2 attenuates MPP+ but not 6-OHDA induced cell death in dopaminergic neurons. Neurobiol Dis. 2003;14:43-51.
78. Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8:705-711.
79. Youdim MB, Arraf Z. Prevention of MPTP (N-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology. 2004;46:1130-1140.
80. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889-909.
81. Jiang H, Li LJ, Wang J, Xie JX. Ghrelin antagonizes MPTP- -induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. Exp Neurol. 2008;212:532-537.
82. Jung HW, Son HY, Jin GZ, Park YK. Preventive role of PD-1 on MPTP-induced dopamine depletion in mice. Cell Biochem Funct. 2010;28:217-223.
83. Shin JY, Park HJ, Ahn YH, Lee PH. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. J Neurochem. 2009;111:1042-1050.
84. Bazan NG. Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids. 2009;81:205-211.
85. Pan HC, Kao TK, Ou YC et al. Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J Nutr Biochem. 2009;20:715-725.
86. German OL, Insua MF, Gentili C, Rotstein NP, Politi LE. Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway. J Neurochem. 2006;98:1507-1520.
87. Lukiw WJ, Cui JG, Marcheselli VL et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005;115:2774-2783.
88. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA. 2004;101:8491-8496.
89. Marcheselli VL, Hong S, Lukiw WJ et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 2003;278:43807-43817.
90. Mukherjee PK, Chawla A, Loayza MS, Bazan NG. Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukot Essent Fatty Acids. 2007;77:233-238.
91. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997;88:435-437.
92. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol- 3,4-bisphosphate. Science. 1997;275:665-668.
93. Klippel A, Kavanaugh WM, Pot D, Williams LT. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol. 1997;17:338-344.
94. Kohn AD, Takeuchi F, Roth RA. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem. 1996;271:21920-21926.
95. Crossthwaite AJ, Hasan S, Williams RJ. Hydrogen peroxidemediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurones: dependence on Ca(2+) and PI3-kinase. J Neurochem. 2002;80:24-35.
96. Lee HJ, Kim MK, Kim HJ, Kim SU. Human neural stem cells genetically modified to overexpress Akt1 provide neuroprotection and functional improvement in mouse stroke model. PLoS One. 2009;4:e5586.
97. Sun X, Yao H, Douglas RM, Gu XQ, Wang J, Haddad GG. Insulin/PI3K signaling protects dentate neurons from oxygen- glucose deprivation in organotypic slice cultures. J Neurochem. 2010;112:377-388.
98. Dudek H, Datta SR, Franke TF et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275:661-665.
99. Heo SR, Han AM, Kwon YK, Joung I. p62 protects SH-SY5Y neuroblastoma cells against H2O2-induced injury through the PDK1/Akt pathway. Neurosci Lett. 2009;450:45-50.
100. Liu JH, Yin F, Guo LX, Deng XH, Hu YH. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin. 2009;30:159-165.
101. Malagelada C, Jin ZH, Greene LA. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci. 2008;28:14363-14371.
102. Li Z, Hu Y, Zhu Q, Zhu J. Neurotrophin-3 reduces apoptosis induced by 6-OHDA in PC12 cells through Akt signaling pathway. Int J Dev Neurosci. 2008;26:635-640.
103. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol. 2001;63:29-60.
104. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol. 2000;1:120-129.
105. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261-1274.
106. Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868.
107. Jacinto E, Facchinetti V, Liu D et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125-137.
108. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci. 2010;30:1166-1175.
109. Ries V, Henchcliffe C, Kareva T et al. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci USA. 2006;103:18757-18762.
110. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
111. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 1998;273:32377-32379.
112. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86-90.
113. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol. 2001; 11:297-305.
114. Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. CREB: a major mediator of neuronal neurotrophin responses. Neuron. 1997;19:1031-1047.
115. Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? CNS Drug Rev. 2005;11: 183-194.
116. Mandel SA, Sagi Y, Amit T. Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP- -induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem Res. 2007;32:1694-1699.
117. Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis. 2007;25:35-44.
118. Chen W, Esselman WJ, Jump DB, Busik JV. Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 2005;46:4342-4347.
119. Florent S, Malaplate-Armand C, Youssef I et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J Neurochem. 2006;96:385-395.
120. Lee JY, Ye J, Gao Z et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem. 2003;278:37041-37051.